Livagen

Livagen is a peptide with no FDA-approved indication and essentially no captured community footprint, which means there is no established protocol, no consensus use case, and no reliable read on what people actually run in practice. The only human exploration is a single thin insomnia trial, with the remainder of the literature confined to animal-only mechanistic work. The central tradeoff is that the off-label evidence base is far thinner than it is commonly presented, and the exploratory indications largely lack posted results.